Catalyst Pharmaceuticals (NASDAQ:CPRX) Given New $36.00 Price Target at Truist Financial

Catalyst Pharmaceuticals (NASDAQ:CPRX) had its target price upped by Truist Financial from $30.00 to $36.00 in a research report sent to investors on Monday morning,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, November 8th. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 9th. Finally, Citigroup lifted their price target on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $30.50.

Catalyst Pharmaceuticals Stock Performance

CPRX opened at $22.80 on Monday. The company has a fifty day moving average of $20.93 and a two-hundred day moving average of $18.26. The stock has a market capitalization of $2.72 billion, a price-to-earnings ratio of 19.32, a PEG ratio of 3.67 and a beta of 0.75. Catalyst Pharmaceuticals has a fifty-two week low of $12.90 and a fifty-two week high of $24.27.

Insiders Place Their Bets

In other news, Director David S. Tierney sold 15,000 shares of Catalyst Pharmaceuticals stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total transaction of $301,500.00. Following the completion of the sale, the director now directly owns 348,874 shares of the company’s stock, valued at approximately $7,012,367.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Catalyst Pharmaceuticals news, Director David S. Tierney sold 15,000 shares of the firm’s stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $20.10, for a total value of $301,500.00. Following the sale, the director now directly owns 348,874 shares in the company, valued at $7,012,367.40. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Steve Miller sold 150,000 shares of the company’s stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $20.35, for a total value of $3,052,500.00. Following the transaction, the insider now directly owns 675,124 shares of the company’s stock, valued at approximately $13,738,773.40. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.00% of the stock is currently owned by company insiders.

Institutional Trading of Catalyst Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CPRX. Mutual of America Capital Management LLC raised its stake in Catalyst Pharmaceuticals by 9.7% during the 1st quarter. Mutual of America Capital Management LLC now owns 19,241 shares of the biopharmaceutical company’s stock worth $307,000 after acquiring an additional 1,701 shares in the last quarter. Texas Permanent School Fund Corp increased its position in shares of Catalyst Pharmaceuticals by 12.9% during the first quarter. Texas Permanent School Fund Corp now owns 97,747 shares of the biopharmaceutical company’s stock worth $1,558,000 after purchasing an additional 11,176 shares in the last quarter. Oppenheimer & Co. Inc. purchased a new stake in shares of Catalyst Pharmaceuticals in the 1st quarter valued at about $805,000. Illinois Municipal Retirement Fund boosted its position in shares of Catalyst Pharmaceuticals by 5.2% in the 1st quarter. Illinois Municipal Retirement Fund now owns 63,950 shares of the biopharmaceutical company’s stock valued at $1,019,000 after purchasing an additional 3,144 shares during the period. Finally, Swiss National Bank grew its stake in Catalyst Pharmaceuticals by 10.4% during the 1st quarter. Swiss National Bank now owns 208,800 shares of the biopharmaceutical company’s stock worth $3,328,000 after buying an additional 19,700 shares during the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.